GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abera Bioscience AB (XSAT:ABERA) » Definitions » Debt-to-Equity

Abera Bioscience AB (XSAT:ABERA) Debt-to-Equity : 0.00 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Abera Bioscience AB Debt-to-Equity?

Abera Bioscience AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Abera Bioscience AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Abera Bioscience AB's Total Stockholders Equity for the quarter that ended in Mar. 2024 was kr9.27 Mil. Abera Bioscience AB's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Abera Bioscience AB's Debt-to-Equity or its related term are showing as below:

XSAT:ABERA's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Abera Bioscience AB Debt-to-Equity Historical Data

The historical data trend for Abera Bioscience AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abera Bioscience AB Debt-to-Equity Chart

Abera Bioscience AB Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial - - - - -

Abera Bioscience AB Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Abera Bioscience AB's Debt-to-Equity

For the Biotechnology subindustry, Abera Bioscience AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abera Bioscience AB's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abera Bioscience AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Abera Bioscience AB's Debt-to-Equity falls into.



Abera Bioscience AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Abera Bioscience AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Abera Bioscience AB's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abera Bioscience AB  (XSAT:ABERA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Abera Bioscience AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Abera Bioscience AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Abera Bioscience AB (XSAT:ABERA) Business Description

Traded in Other Exchanges
N/A
Address
Svetsarvagen 15, Solna, SWE, SE-17141
Abera Bioscience AB is a platform and vaccine development company based on research in the medical, molecular, and microbiological fields. The company's mission is to develop vaccine candidates based on its novel vaccine delivery platform to late pre-clinical or early clinical phase.

Abera Bioscience AB (XSAT:ABERA) Headlines

No Headlines